Drugs / IDOV-SAFE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06718946 | Dec 2024 → Dec 2025 overdue | cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 0 | NCT06380309 | May 2024 → Dec 2025 overdue | digestive system cancer | Peking University | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDOV-SAFE | “combination therapy with IDOV-SAFE + Toripalimab + Fruquintinib after progression on IDOV-SAFETM monotherapy.” NCT06380309 ↗ |
| Route | Intravenous | “Intravenous injection of 1E9 PFU oncolytic virus” NCT06380309 ↗ |